Omeros to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 11 2021 - 4:30PM
Business Wire
Omeros Corporation (Nasdaq: OMER) today announced that Gregory
A. Demopulos, M.D., chairman and chief executive officer, will
present at the 39th Annual J.P. Morgan Healthcare Conference this
week. This conference is being held as a virtual conference this
year. The presentation is scheduled for Wednesday, January 13, 2021
at 10:50 a.m. EST.
The presentation will be webcast. The live and archived webcasts
can be accessed on the investor relations section of the company’s
website at www.omeros.com under “Events.” The archived webcast will
be available for 30 days.
About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company committed
to discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting inflammation, complement-mediated diseases, disorders of
the central nervous system and immune-related diseases, including
cancers. Its commercial product OMIDRIA (phenylephrine and
ketorolac intraocular solution) 1%/0.3% continues to gain market
share in cataract surgery. Omeros’ lead MASP-2 inhibitor
narsoplimab targets the lectin pathway of complement and is the
subject of a rolling biologics license application under review by
FDA for the treatment of hematopoietic stem cell
transplant-associated thrombotic microangiopathy. Narsoplimab is
also in multiple late-stage clinical development programs focused
on other complement-mediated disorders, including IgA nephropathy,
atypical hemolytic uremic syndrome and COVID-19. Omeros’ MASP-3
inhibitor OMS906, which targets the complement system’s alternative
pathway, recently entered the clinic, and the company’s PDE7
inhibitor OMS527 has successfully completed its Phase 1 trial.
Omeros’ pipeline holds a diverse group of preclinical programs
including a novel antibody-generating technology and a proprietary
GPCR platform through which it controls 54 new GPCR drug targets
and their corresponding compounds. One of these novel targets,
GPR174, modulates a new cancer immunity axis recently discovered by
Omeros, and the company is advancing small-molecule GPR174
inhibitors.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210111006026/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations 360.668.3701 jennifer@cwcomm.org
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2023 to Apr 2024